Table 1

Baseline patient characteristics (N=470)

Patients, n (%)mRCC cohortmUC cohort
Total
(N=470)(N=271)(N=199)
Age at start of ICI (years)
 Mean (SD)64.8 (11.6)61.7 (10.9)69.0 (11.1)
 Median (min, max)65 (22 to 91)62 (22 to 85)69 (26 to 91)
Sex
 Male342 (72.8)201 (74.2)141 (70.9)
 Female128 (27.2)70 (25.8)58 (29.2)
Line of ICI
 First207 (44.0)113 (41.7)94 (47.2)
 Second or more263 (56.0)158 (58.3)105 (52.8)
ECOG PS
 0149 (32.4)78 (28.8)71 (37.6)
 1242 (52.6)156 (57.6)86 (45.5)
 265 (14.1)37 (13.7)28 (14.8)
 34 (0.9)_4 (2.1)
Site of metastasis
 Lung257 (54.7)176 (64.9)81 (40.7)
 Lymph nodes393 (83.6)211 (77.9)182 (91.5)
 Bone119 (25.3)81 (29.9)38 (19.1)
 Liver112 (23.8)67 (24.7)45 (22.6)
 Brain14 (3.0)12 (4.4)2 (1.0)
 Other104 (63.8)104 (38.4)59 (29.7)
Type of ICI
 PD-1 inhibitors*312 (66.2)197 (72.7)114 (57.3)
 PD-L1 inhibitors†159 (33.8)74 (27.3)85 (42.7)
ICI type
 ICI monotherapy341 (72.5)157 (57.9)184 (92.5)
 ICI+ICI43 (9.2)30 (11.1)13 (6.5)
 ICI+other‡86 (18.3)84 (31.0)2 (1.0)
  • *Includes pembrolizumab and nivolumab.

  • †Includes atezolizumab, avelumab, and durvalumab.

  • ‡Investigational immunotherapy and targeted therapy agents.

  • ICI, immune checkpoint inhibitor; mRCC, metastatic renal cell carcinoma; mUC, metastatic urothelial carcinoma; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; ECOG PS, Eastern Cooperative Oncology Group Performance Status.